DREADD Actuator Pharmacology

The original DREADD ligand, clozapine-N-oxide, was long assumed to be inert. It is now clear that in vivo a fraction is back-metabolised to clozapine, which crosses the blood-brain barrier far more readily and is the actual agonist reaching the receptor — while also having its own off-target actions at native neurotransmitter receptors. This means an apparent chemogenetic effect can be partly a low-dose clozapine effect, and every experiment needs a ligand-only control in animals lacking the DREADD.

In response, a generation of improved actuators was developed — compounds with greater potency, better brain penetration, and cleaner selectivity, such as deschloroclozapine and several designer agonists usable at low doses. Getting the pharmacology right is not a footnote: it determines whether a chemogenetic result is interpretable and whether the approach can be translated to humans, where the ligand must be safe, potent, and truly selective.